Stipple Bio, a private biotech company using epitope-level precision to create targeted cancer therapies, has closed a $100 million Series A round—heavily oversubscribed and co-led by RA Capital, a16z Bio+Health, and Nextech Invest. 

 

Existing investors including Emerson Collective Investments (managed by Yosemite), GV (Google Ventures), LoLa Capital Partners, and GordonMD Global Investments also participated.

 

As part of the financing, Derek DiRocco, and Thilo Schroeder, will join the Stipple Bio Board of Directors, which already includes Vineeta Agarwala, Owen Hughes, Jeff Landau, Aaron Ring, and Greg Verdine.

 

The new capital is expected to fund the company through 2029. Proceeds will advance lead candidate STP-100 into multiple early-stage clinical trials and expand the company’s pipeline by leveraging its Pointillist Platform to identify additional tumor-specific cell surface epitopes.

 

“We are building upon deep cancer biology expertise to map, target and unlock tumor-specific epitopes which enable us to develop a pipeline of next-generation precision oncology therapeutics,” said Jeff Landau, CEO of Stipple Bio. 

 

“This funding positions us to progress STP-100 into the clinic and continue building a broad oncology pipeline. I am extremely pleased to have the support of industry-leading investors who share our enthusiasm towards developing precision and differentiated cancer therapies based on our modality-agnostic Pointillist Platform.”

 

“Clinical experience with prior antibody drugs has taught us that epitope-level specificity matters. Since the earliest days of Stipple Bio, we’ve been impressed by the team’s vision to move beyond tumor-specific gene expression and to pioneer tumor-specific ‘epitomics’ in precision oncology. 

 

"We are proud to have supported Stipple Bio since inception and to co-lead this financing as the company advances safer, more effective therapies for patients living with cancer,” said Dr. Agarwala, General Partner at Andreessen Horowitz and lead investor for the a16z Bio+Health Fund.

 

“Stipple Bio’s Pointillist Platform introduces an epitope-level approach to targeting tumor biology that has the potential to meaningfully expand the set of druggable oncology targets. 

 

"Lead candidate STP-100 illustrates how this strategy can drive precise tumor targeting while sparing normal tissues—a key step toward improving therapeutic index in ADCs. We are excited to partner with the team as they advance STP-100 into the clinic and build a broader pipeline from the platform,” said Dr DiRocco, Partner at RA Capital Management.